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Anti-tubercular-glycolipid-IgG (TBGL-IgG) and -IgA (TBGL-IgA) antibodies, and the QuantiFERON-TB Gold test (QFT) were
compared in healthcare workers (HCWs, n = 31) and asymptomatic human immunodeﬁciency virus-carriers (HIV-AC, n = 56)
in Manila. In HCWs, 48%, 51%, and 19% were positive in QFT, TBGL-IgG, and -IgA, respectively. The TBGL-IgG positivity was
signiﬁcantly higher (P = 0.02) in QFT-positive than QFT-negative HCWs. Both TBGL-IgG- and -IgA-positive cases were only
found in QFT-positive HCWs (27%). The plasma IFN-γ levels positively correlated with TBGL-IgA titers (r = 0.74, P = 0.005),
but not TBGL-IgG titers in this group, indicating that mucosal immunity is involved in LTBI in immunocompetent individuals.
The QFT positivity in HIV-AC was 31% in those with CD4+ cell counts >350/μL and 12.5% in low CD4 group (<350/μL). 59 %
and 29% were positive for TBGL-IgG and -IgA, respectively, in HIV-AC, but no association was found between QFT and TBGL
assays.TBGL-IgG-positiveratesinQFT-positiveandQFT-negative HIV-ACwere 61%and58%,andthoseofTBGL-IgAwere23%
and 30%, respectively. The titers of TBGL-IgA were associated with serum IgA (P = 0.02) in HIV-AC. Elevations of TBGL-IgG
and -IgA were related to latent tuberculosis infection in HCWs, but careful interpretation is necessary in HIV-AC.
1.Introduction
Although the incidence of tuberculosis has been falling since
2002, there were still 8.8 million incident cases of TB, 1.1
million deaths from TB, and an additional 0.35 million
deaths from HIV-associated TB in 2010 [1]. The high rate
of latent TB infection (LTBI) is one of the factors that make
it diﬃcult to achieve global control and eliminate TB [2].
The recent introduction of the immune-based interferon-
γ release assay (IGRA) made a great impact on facilitating
the diagnosis of LTBI [3] and clariﬁed the high rate of
infection in TB-high-risk populations including healthcare
workers (HCWs) [4]. Attempts to detect LTBI in HIV-
infected individuals were also facilitated by the development
ofIGRA,althoughtheirhigherratesofpseudonegativeIGRA
response due to low CD4+ T cell counts and diminished Th1
immunity cannot be ignored [5]. Trehalose 6,6-dimycolate
(TDM), which constitutes a major part of the mycobacterial
cell wall, was identiﬁed as the most immunogenic glycol-
ipid and is produced predominantly by virulent MTB as
well as by atypical mycobacteria [6]. Tubercular-glycolipid
antigen (TBGL) consists of TDM puriﬁed from virulent
mycobacterial strain H37Rv [7, 19]. The immunoglobulin-
G to tubercular-glycolipid antigen (TBGL-IgG) has been
proposed to be a useful marker for the serodiagnosis of
active pulmonary tuberculosis (PTB) in Japan [7]. However,
frequent elevated titers (17%) were also found in healthy
elderly control people (age >40 years) in the same study,2 Clinical and Developmental Immunology
and the possibility of LTBI was suggested by Maekura and
colleagues [7]. Although IgA antibody to TBGL antigen
(TBGL-IgA) was not evaluated earlier as a biomarker, strong
association was revealed between the TBGL-IgG and-IgA
titers in PTB cases [8]. Frequent positivity for TBGL-IgG
(46%) and -IgA (36%) in healthy adults was also observed in
ourveryrecentstudyinThailand,aTB-endemiccountry[9].
The TBGL-IgG-positive responses were not related to BCG
vaccination [10]. Since both cellular-mediated and humoral
immunity are necessary for an eﬀective immune response
against MTB, we aimed to clarify the relationship between
the TBGL-IgG and -IgA responses with QuantiFERON-TB
Gold In-Tube (QFT) assay system, in healthcare workers
(HCWs) in a hospital of the Philippines.
Infection of human immunodeﬁciency virus (HIV) has
substantially boosted the occurrence of tuberculosis (TB)
disease worldwide [1]. The devastating association between
HIV and TB is responsible for one of four TB-related
deaths [11]. The East-Asian countries are predominantly TB
endemic [1]. Similarly to Sub-Saharan Africa, the rapid, pro-
gressive increase of HIV infections in East-Asian countries
may further accelerate TB infection in HIV/AIDS patients
[12]. To clarify how HIV infection may alter immune
responses in LTBI, newly diagnosed, asymptomatic, non-TB
HIV-infected individuals were studied.
Tounderstandthehealthconditionoftheindividuals,we
measured two TB-related biomarkers. Leptin, a cytokine-like
hormone produced by bronchial epithelial cells and type II
pneumocytes in addition to adipose tissue, exhibits a Th1-
biasimmuneresponse[13].Osteopontin(OPN)isamember
of extracellular matrix proteins that is synthesized within
the immune system by activated T cells, NK cells, dendritic
cells,andmacrophages.InvolvementofOPNinTh1immune
responses has been reported [14]. OPN deﬁciency was found
to be associated with the dissemination of mycobacterial
disease, and its expression correlated with an eﬀective
immune and inﬂammatory response against mycobacteria
in rodents as well as in human [15, 16]. Elevated levels of
circulatory plasma OPN [17]a n dl o wl e v e l so fl e p t i n[ 18]
were reported to be associated with active tuberculosis; these
biomarkers served as a negative evidence of active disease.
2.MaterialsandMethods
2.1. Study Subjects. Ac a s e - c o n t r o ls t u d yw a sc o n d u c t e d
between March and October of 2010 in adult participants
(age > 18 years) in the Philippines. Thirty-one healthy,
adult healthcare workers (HCWs) without any concomitant
symptoms or chest radiographic ﬁndings relevant to active
TB and who had negative HIV serology were recruited
from San Lazaro Hospital (SLH), Manila, Philippines. Fifty-
six newly diagnosed, asymptomatic HIV carriers (HIV-
AC) without any clinical symptoms relevant to tuberculosis
were randomly selected from among patients receiving care
at the outpatient department of the SLH. None of the
subjects took any anti-HIV therapy. Subjects with AIDS-
deﬁning events, currently active tuberculosis, or any symp-
toms relevant to tuberculosis, other than active pulmonary
diseases, underlying malignancy or metabolic disorders were
excluded from the study. The exclusion criteria for active
tuberculosis were based on both clinical ﬁndings and chest
X-ray (CXR) ﬁndings in the HCWs. The study was approved
by the ethics committee of SLH and the Tohoku University
Hospital. We obtained written informed consent from all the
participants. Three mL of blood was obtained directly (one
mL in each tube) from each participant to perform the QFT
assay. Simultaneously, plasma was separated from blood by
centrifugation after treatment with EDTA and was aliquoted
to CryoTubes for storage at −80◦C until further utilization.
All the procedures were conducted in accordance with the
Helsinki declaration.
2.2. TBGL-Antibody Assay. TBGL-IgG antibody and -IgA
antibodies were measured using the Determiner TBGL Anti-
body ELISA kit (Kyowa Medex, Tokyo, Japan), an in vitro
enzyme-linked immunosorbent assay for the quantitative
measurement of anti-TBGL-IgG and -IgA in plasma. This
assay employs glycolipid antigens puriﬁed from M. tubercu-
losis H37Rv (TBGL antigen) coated on a 96-well plate. The
details of the assay were described in our previous study [8].
TheantibodytitersforTBGL-IgGand-IgAwereexpressedas
U/mL. Positive TBGL-IgG titers were determined according
to the cutoﬀ index proposed by Kishimoto et al. [19].
The samples were classiﬁed as positive when the serum
levels of anti-TBGL-IgG were ≥2U/mL. An arbitrary cutoﬀ
value of ≥2U/mL for TBGL-IgA was used according to the
unpublished data of our previous study [8].
2.3. QuantiFERON-TB Gold In-Tube (QFT). The QFT test
was performed using fresh whole blood in accordance with
the manufacturer’s instruction (Cellestis, Australia). The
results were interpreted using speciﬁc software provided
by Cellestis. The result was scored positive if the IFN-γ
concentration in the tube TB-speciﬁc antigen containing
was >0.35IU/mL after subtracting the value of the nil
control (IFN-γ-nc) and at least >25% of NC value. If the
net IFN-γ response (TB Ag minus nil) was <0.35IU/mL
for the antigens and the response to the mitogen-positive
control was >0.5IU/mL, the response was considered as test
negative. An intermediate result was recorded if the net IFN-
γ response was <0.35IU/mL for the antigen and <0.5IU/mL
for the mitogen and/or was above 8IU/mL for the NC.
2.4. Leptin and OPN Elisa Assay. Plasma leptin levels were
determined by sandwich ELISA using Quantikine Human
Leptin Immunoassay kit (R&D Systems) for the quantita-
tive determination of the human leptin concentrations in
plasma according to the manufacturer’s guidelines. Plasma
OPN concentrations were determined using Human OPN
Elisa kit (Immuno-Biological Laboratories, Takasaki, Japan)
according to the manufacturer’s guidelines, and values were
expressed as ng/mL.
2.5. Clinical Data. We measured diﬀerent laboratory mark-
ers including complete red blood cell counts, the number
of white blood cells with their diﬀerential counts, levels ofClinical and Developmental Immunology 3
hemoglobin, and serum levels of IgG and IgA. The number
of CD4+ T cell counts and HIV RNA load of HIV-AC were
also determined.
2.6. Statistical Analysis. The data of quantitative variables
are summarized as median and range. Categorical variables
were computed as frequency and percentage. The data
were analyzed using Stat Flex software, version 5 (Artech
Co., Ltd: http://www.statﬂex.net/index.html)a n dS t a t c e l2
(OMS Publishing Inc. Saitama, Japan). The ability of each
single marker to discriminate HIV from HCW by receiver
operating characteristic (ROC) curve and the area under
curve (AUC) was also analyzed. The percentage of overall
agreement between QFT and TBGL-IgG/IgA ELISA assays
was calculated, and a Cohen’s Kappa coeﬃcient was used to
assess the level of agreement. The signiﬁcance of association
for categorical variables was estimated by Fisher’s exact
test, whereas correlations between continuous variables were
evaluated by Spearman’s rank correlation coeﬃcient. The
diﬀerencesinsigniﬁcancebetweencontinuousvariableswere
compared by the Mann-Whitney U test. A 2-tailed P value of
<0.05 was considered signiﬁcant.
3. Results
3.1. Characteristics of Study Participants. A total of 31 HCWs
and56newlydiagnosedHIV-ACwereenrolledinthecurrent
study. Basic demographic and clinical characteristics of the
study participants are shown in Table 1. The participating
HIV-AC were relatively young (P = 0.03) with a signiﬁcant
male predominance (P<0.0001) compared to the HCWs.
Although lymphocyte counts were comparable between
the two groups, total counts of WBC, neutrophils, and
monocytes were signiﬁcantly lower in HIV-AC.
3.2. QFT and TBGL-Antibody Assays in HCWs. Forty-eight
percent (15/31) of the HCWs showed positive reactions in
the QFT assay indicating high incidences of LTBI (Table 1).
The median age of the QFT-positive responders from among
the HCWs were signiﬁcantly higher than those of the QFT-
negative group (P = 0.002). TBGL-IgG and TBGL-IgA were
positive in 51% and 19% of HCWs, respectively (Table 1).
Eleven of 15 (73%) QFT-positive HCWs had positive
TBGL-IgG responses (categorical agreement 73%), whereas
5 of 16 (31%) QFT-negative subjects had positive TBGL-
IgG responses (categorical agreement 68.7%). The overall κ
value was 0.42, indicating a moderate association between
the two assays (overall agreement: 71%; 95% CI: 0.10∼0.73).
The TBGL-IgG-positive proportions were also signiﬁcantly
diﬀerent between QFT-positive and QFT-negative groups
of HCWs (P = 0.02). Although the number of positive
TBGL-IgAresponders wassmallin HCWsand failed toshow
any signiﬁcant diﬀerence (P = 0.072), the TBGL-IgG+IgA
double-positive response was shown only by QFT-positive
HCWs and none of the QFT-negative HCWs had double-
positive reactions (P = 0.043) (Figure 1)( Table 2).
In addition, signiﬁcant positive correlation was observed
between the concentrations of IFN-γ-nc and TBGL-IgA
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Figure 1: Positivity percentage of TBGL-IgG/IgA assay in QFT-
positive/negative healthcare workers. The level of agreement
between QFT and the TBGL-Ab assay was measured by Cohen’s
kappa (κ). ¶κ = 0.42; overall agreement 71%; 95% conﬁdence
interval: 0.1∼0.73.∗Signiﬁcant diﬀerence (P<0.05).
titers in the QFT-positive group (r = 0.74, P = 0.005)
(Figure 2), but not in the QFT-negative group. There was no
such association between IFN-γ-nc and TBGL-IgG levels in
HCWs, although a tendency for a positive correlation was
observed in the QFT-positive HCWs (r = 0.43, P = 0.11)
(Figure 2). No association was observed in the net IFN-
γ concentrations in antigen-stimulated QFT-plasma with
TBGL-IgG or -IgA titers (data not shown). The plasma levels
of OPN and leptin were not diﬀerent between QFT-positive
and QFT-negative HCWs (Table 2).
3.3. QFT and TBGL-Antibody Assays in HIV-AC. As shown
in Table 1, only 13 of 56 (23%) HIV carriers showed positive
reactions by QFT assay. The rate of positivity was closely
associated with high median CD4+ T cell counts (P = 0.012)
and younger age (P = 0.036) (Table 2). Seven of 56 (12.5%)
HIV-AC who had lower mitogen responses (IFN-γ con-
centrations: median: 1.78IU/mL; range: 0.38∼6.73IU/mL)
than the rest (>10U/mL) had negative responses by QFT
assay. Their median CD4+ T-cell counts were 60/μL( r a n g e :
43∼425/μL) (data not shown). Thirty-three of 56 (59%)
and 16 of 56 (29%) HIV-AC were attributed with positive
TBGL-IgG and TBGL-IgA responses, respectively (Table 1).
The positive proportions of TBGL-IgG and -IgA responses
were not signiﬁcantly diﬀerent between QFT-positive and -
negative HIV-AC (Table 2). However, 6 of 7 QFT-negative
low mitogen responders in HIV-AC were positive for both
TBGL-IgG and -IgA assay (data not shown). The TBGL-
IgA titers were signiﬁcantly higher in the TBGL-IgG-positive
HIV-AC (P = 0.041) (Table 3). In addition, TBGL-IgA-
positive HIV-AC had signiﬁcantly elevated titers of TBGL-
IgG (P = 0.042), serum IgA (P = 0.015), and OPN
(P = 0.03), (Table 3). Interestingly, the TBGL-IgA-positive
proportion was inversely correlated with the CD4+ T-
cell counts (P = 0.018), and the titers were signiﬁcantly
higher in the HIV-AC with CD4+ T-cell count < 350/μL4 Clinical and Developmental Immunology
Table 1: Demographic and clinical data of study participants.
Variables HCWs (n = 31) HIV-AC (n = 56) P
Demographic data
Gender: male; n (%) 16 (51.6) 55 (96.5) <0.0001∗
Age year; median (range) 35 (19∼62) 28 (19∼48) 0.03∗
Laboratory ﬁndings†
Hemoglobin (g/dL) 13.2 ±2.61 3 ± 1.49 0.36
RBC (million/μL) 4.96 ±1.64 .43 ±.55 0.069
WBC (103/μL) 7.5 ±2.55 .9 ±1.90 . 0 1 ∗
Neutrophil (103/μL) 4.4 ±2.23 .3 ±1.2 0.048∗
Lymphocyte (103/μL) 2.4 ±0.62 .2 ±0.90 . 8 2
Monocyte (/μL) 562 ±237 338 ±182 <0.001∗
CD4+ T-cell count (/μL) ND 443 ±286 NA
QFT assay positive; n (%) 15 (48) 13 (23) 0.03∗
TBGL-IgG positive; n (%) 16 (51) 33 (59) 0.9
TBGL-IgA positive; n (%) 6 (19) 16 (29) 0.87
IFN-γ-nc (IU/mL) 0.42 ±0.96 0.13 ±0.11 <0.001∗
TBGL-IgG (U/mL) 3.12 ±3.36 3.94 ±6.63 0.14
TBGL-IgA (U/mL) 1.68 ±2.56 3.1 ±6.64 0.012∗
Serum IgG (mg/dL) 1409 ±212 1391 ±224 0.49
Serum IgA (mg/dL) 246 ±92 319 ±138 0.058
OPN (ng/mL) 14.4 ±11 159 ±191 <0.00001∗
Leptin (ng/mL) 18.6 ±13.97 .2 ±5.4 <0.001∗
Abbreviations: HCWs, healthcare workers; HIV-AC, newly diagnosed cases of asymptomatic human immune-deﬁciency virus infection; OPN, osteopontin;
ND, not determined; NA, not applicable.
†values were presented as mean ± SD unless indicated otherwise; IFN-γ-nc: levels of IFN-γ, measured in the nonstimulated QFT-plasma samples; P values
for statistical diﬀerences between HCW and HIV-AC; ∗signiﬁcant diﬀerences (P<0.05).
Table 2: Comparison between QFT-positive and QFT-negative HCWs and HIV-AC.
Variables
HCWs HIV-AC
QFT+ (n = 15) QFT− (n = 16) P QFT+ (n = 13) QFT− (n = 43) P
Age; median (range) 45 (21∼62) 23.5 (19∼48) 0.002∗ 25 (19∼45) 31 (21∼35) 0.036∗
Gender: male; n (%) 7 (46.6) 9 (47.4) 0.43 12 (92.3) 42 (97.67) 0.43
Work duration->10 yrs; n (%) 11(73.3) 6 (37.5) 0.098 NA NA NA
CD4+ count (/μL); median (range) ND ND NA 611 (148∼1466) 356 (13∼1125) 0.012∗
TBGL-IgG positive; n (%) 11 (73) 5 (31) 0.02∗ 8 (61.5) 25 (58.13) 0.545
TBGL-IgA positive; n (%) 5 (33) 1 (6) 0.072 3 (23) 13 (30) 0.415
TBGL-IgG+IgA positive; n (%) 4 (27) 0 (0) 0.043∗ 2(15.4) 10 (23.3) 0.42
IFN-γ-nc (IU/mL)† 0.3 ± 0.40 .2 ±0.13 0.9 0.21 ±0.17 0.1 ±0.07 0.0087∗
Serum IgG (mg/dL)† 1450 ±188 1368 ±235 0.2 1306 ±207 1414 ±249 0.5
Serum IgA (mg/dL)† 268 ±81 225 ±101 0.32 330 ±130 312 ±138 0.68
OPN (ng/mL)† 14.5 ± 11.21 4 .2 ±11.2 0.87 115.4 ±130 173.2 ±203 0.43
Leptin (ng/mL)† 21.3 ± 13.31 5 .9 ±14.30 . 2 56 .46 ±4.12 7.448 ±5.68 0.24
Abbreviations: HCWs, healthcare workers; HIV-AC, newly diagnosed cases of asymptomatic human immune-deﬁciency virus infection; OPN, osteopontin;
ND, not determined; NA, not applicable.
†mean ± SD; IFN-γ-nc: levels of IFN-γ, measured in the nonstimulated QFT-plasma samples; P values for statistical diﬀerences between QFT-positive and
QTF-negative groups; ∗signiﬁcant diﬀerences (P<0.05).Clinical and Developmental Immunology 5
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Figure 2: Correlations between TBGL-IgA or TBGL-IgG titers and IFN-γ concentrations measured in nonstimulated QFT-plasma samples
(IFN-γ-nc) in QFT-positive/QTF-negative healthcare workers (HCWs) and asymptomatic HIV carriers (HIV-AC). The only signiﬁcant
positive correlation was observed between the IFN-γ-nc concentrations and TBGL-IgA titers in the QFT-positive HCW group (r = 0.74,
P = 0.005).
(HIV-LCD) (P = 0.048) (Table 4). Furthermore, in the
HIV-AC, a relatively higher proportion of double positive
(TBGL-IgG+IgA) responders was found in the HIV-LCD
group (29%) than in the HIV-HCD group (CD4+ count ≥
350/μL) (16%), although the diﬀerence was not statistically
signiﬁcant (P = 0.32) (Table 4).
Moreover, the IFN-γ-nc concentrations were signiﬁ-
cantly lower in the QFT-negative HIV-AC (P = 0.008)
(Table 2). No association was observed between the IFN-γ-
nc concentrations and TBGL-IgG or -IgA titers in any group
of HIV-AC (Figure 2). The plasma levels of OPN and leptin
were not diﬀerent between QFT-positive and QTF-negative
HIV-AC (Table 2).
3.4. Comparison between the Serum Antibodies and TBGL
Antibodies. TheTBGL-IgGand-IgAhadnocorrelationwith6 Clinical and Developmental Immunology
Table 3: Comparison between TBGL-IgG or TBGL-IgA-positive and -negative HIV-AC.
Variables
TBGL-IgG TBGL-IgA
Positive (n = 33) Negative (n = 23) P Positive (n = 16) Negative (n = 40) P
Age; median (range) 28 (19∼48) 30 (19∼41) 0.18 31.5 (19∼48) 28 (19∼45) 0.038∗
Gender: male; n (%) 33 (100) 21 (91.3) 0.43 16 (100) 38 (95) 1
CD4 count (/μL); mean (range) 436 (13∼1466) 450 (60∼851) 0.45 346 (46∼1125) 480 (13∼1466) 0.06
QFT positive; n (%) 8 (24.2) 5 (21.7) 0.545 3 (19) 10 (25) 0.45
TBGL-IgA positive; n (%) 12 (36.4) 4 (17.4) 0.1 — — —
TBGL-IgG positive; n (%) — — — 12 (75) 21 (52.5) 0.14
IFN-γ-nc (IU/mL)† 0.13 ±0.09 0.1 ±0.05 0.4 0.12 ±0.09 0.12 ±0.07 0.9
TBGL-IgA (U/mL)† 4.36 ±8.41 .28 ±1.21 0.041∗ ——
TBGL-IgG (U/mL)† —— 7 .5 ±11.62 .5 ±1.5 0.042∗
Serum IgG (mg/dL)† 1439 ±277 1515 ±677 0.5 1615 ±404 1355 ±135 0.46
Serum IgA (mg/dL)† 277 ±95 279 ±74 0.37 410 ±165 313 ±138 0.015∗
OPN (ng/mL)† 176.3 ±199.9 136 ±172.5 0.67 280 ±275 115 ±109.70 . 0 3 ∗
Leptin (ng/mL)† 7.33 ±6.16 7.18 ±4.12 0.68 7.33 ±6.16 7.18 ±4.12 0.07
Abbreviations: HIV-AC, newly diagnosed cases of asymptomatic human immune-deﬁciency virus infection; OPN, osteopontin.
†mean ± SD; IFN-γ-nc: levels of IFN-γ, measured in the nonstimulated QFT-plasma samples; P for statistical diﬀerences between QFT-positive and QTF-
negative groups; ∗signiﬁcant diﬀerences (P<0.05).
Table 4: Comparison between HIV-AC with high§ and low‡ CD4+ T-cell count.
Variables CD4+ high§ (n = 32) CD4+ low‡ (n = 24) P value¶
Age; mean (range) 25.5 (19∼45) 25 (22∼48) 0.018∗
Gender: male; n (%) 31 (97) 23 (98) 1.0
CD4+ count (/μL); median (range) 618 (356∼1466) 201 (13∼349) <0.001∗
QFT-positive; n (%) 10 (31) 3 (12.5) 0.12
TBGL-IgG positive; n (%) 16 (50) 16 (67) 0.27
TBGL-IgA positive; n (%) 5 (16) 11 (46) 0.018∗
TBGL-IgG+ IgA positive; n (%) 5 (16) 7 (29) 0.32
IFN-γ-nc (IU/mL) 0.14 ±0.12 0.13 ±0.09 0.9
TBGL-IgG (U/mL)† 4.6 ±8.43 ±2.80 . 5 9
TBGL-IgA (U/mL)† 1.55 ±25 .16 ±9.6 0.048∗
Serum IgG (mg/dL)† 1352 ±185 1549 ±380 0.5
Serum IgA (mg/dL)† 265 ±89 423 ±149 <0.001∗
OPN (ng/mL)† 119 ±126 214 ±246 0.19
Leptin (ng/mL)† 7.7 ±66 .6 ±4.90 . 5
Abbreviation: HIV-AC, newly diagnosed cases of asymptomatic human immune-deﬁciency virus infection; OPN: osteopontin.
§High: CD4+ T cell count ≥350/μL; ‡low: CD4+ T-cell count <350/μL; †mean ± SD; IFN-γ-nc: levels of IFN-γ, measured in the non-stimulated QFT-plasma
samples; P values for statistical diﬀerences between QFT-positive and QTF-negative groups; ∗signiﬁcant diﬀerences (P<0.05).
the serum IgG and IgA in HCW and HIV-AC except for the
association between the serum IgA levels and the TBGL-IgA
titers in HIV-AC (P = 0.02) (data not shown).
3.5. Comparison of Biomarkers between HCW and HIV-AC.
T h el e v e l so fI F N - γ-nc (P<0.001) were signiﬁcantly higher
in HCWs than in HIV-AC. However, the titers of TBGL-IgA
(P = 0.012), but not -IgG, were signiﬁcantly higher in HIV-
AC than in HCWs. Similarly, the serum IgA levels were also
higher (P = 0.058). The OPN levels were signiﬁcantly higher
(P<0.0001), and the leptin levels were considerably lower
(P<0.001)intheHIV-ACcomparedtotheHCWs(Table 1).
ROC curve analysis was used to discriminate HIV from
HCW groups using the net IFN-γ, leptin, and plasma levelsClinical and Developmental Immunology 7
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Figure 3: Receiver operating characteristic analysis for comparison
of biomarkers between healthcare workers and asymptomatic HIV
carriers. The result showed that the OPN plasma levels of OPN
(log) exhibited the greatest ability to discriminate HIV from HCW
based on the AUC (0.883), followed by leptin (0.763) and net IFN-γ
(0.648).
of OPN (log) as biomarkers. As shown in Figure 3, the
plasma levels of OPN (log) exhibited the greatest ability to
discriminate HIV from HCWs based on the AUC (0.883),
followed by leptin (0.763) and net IFN-γ (0.648). However,
QFT assay as well as TBGL-IgA and -IgG did not show such
proﬁles (data not shown).
4. Discussion
In our data, the application of QFT assay to HCWs in
the Philippines demonstrated a high incidence (48%) of
LTBI, which was comparable to other already published
data in HCWs in TB-endemic developing countries [4]. The
increased risk of LTBI among HCWs was conﬁrmed by the
recent introduction of IGRA [20, 21]. In our country, a
higher incidence of LTBI in HCWs was reported in high-
risk groups for TB, such as homeless areas [22], compared
to other areas [23].
We aimed to clarify the relationship between the TBGL-
IgG and -IgA responses and that of IFN-γ in the QFT assay
in LTBI. The rate of TBGL-IgG positivity was signiﬁcantly
higher in the QFT-positive than QTF-negative group of
HCWs. The signiﬁcant association between the two assay
systems indicated by the κ value in HCWs demonstrated the
TBGL-IgG in LTBI. However, about 30% of QFT-positive
populations from among the HCWs lacked TBGL-IgG, and
30% of those of the QFT-negative group have elevated TBGL
IgG antibody, and the discordant cases were higher in TBGL-
IgA. However, the reasons for such discordances between the
two systems in HCWs are not clear. It is possible that the
generation of antibody requires larger amounts of antigens
than does the generation of T-cell responses. Although
associated immunosuppressive conditions were found as risk
factorsforfalse-negativeQFTresponses[24],suchcaseswere
excluded from HCWs in our study.
The mechanism of the synthesis of anti-TDM antibody
is not clear, though TDM is known to bind to Mincle
(macrophage-inducible C-type lectin) that is present on
macrophages [25], and upon the activation, on T cells [26].
It was found that Mincle is speciﬁc for the ester linkage
of a fatty acid to the trehalose, which explains the strong
binding of TDM, but not trehalase-treated TDM, soluble
trehalose, or puriﬁed mycolate [26]. The conversion of TDM
into glucose monomycolate (GMM) upon mycobacterial
infection might be the mechanism by which mycobacteria
escape from the Mincle-mediated immunity. However, the
immune system possesses other tools to monitor and elim-
inate live mycobacteria through CD1 molecules expressed
on the activated macrophages and dendritic cells, which are
diﬀerent from MHC I, II molecules. Recently, GMM but
not TDM was demonstrated to interact with CD1b and may
induce adaptive immunity [27]. Although it is not known
whether the adaptive immune system leads to antibody
synthesis, the generated antibody may recognize both TDM
and GMM because the two molecules are structurally very
similar.
Interestingly, the IFN-γ-nc levels that were observed to
have a signiﬁcant association with the TBGL-IgA titers in
LTBI of HCWs. IgA is a typical marker of the mucosal
immune response. An elevated serum IgA has been proposed
to have a protective role in IFN-γ-positive immunocompe-
tent LTBI individuals [28]. Frequent exposure to tubercle
bacilli can possibly stimulate the mucosal immune system
in TB-endemic countries. It is also known that commensal
bacteria on the mucosal surface induce IgA in an NO-
dependent manner [29], although it is not known whether
M T Bi nL T B Ih a sas i m i l a re ﬀect in lung mucosa. Circulating
glycolipid immune complexes might lead to nonspeciﬁc
stimulation of T cells, but a component of TBGL, TDM,
could also enhance the in vivo production of IL-12p40 and
IFN-γ in mouse model [30]. IgA antibody and IFN-γ induce
TNF-α and NO production, which mediated the inhibitory
mechanism for M. tuberculosis infection in mouse model
[28]. Furthermore, there is strong evidence of a synergic
eﬀectbetweenIgAandIFN-γ inbactericidalactivitiesagainst
MTB infection [31]. Therefore, the association between
anti-TBGL-IgA and IFN-γ may indicate protective, mucosal
immune activities in LTBI in HCWs.
In HIV carriers, the QFT-positive responses were sig-
niﬁcantly lower than in HCWs and were greatly dependent
on the high CD4+ T-cell counts in the present study.
Much evidence suggests that the baseline CD4+ T-cell
count is a determining factor for a positive QFT response
in HIV infection [32]. Since HIV infection is a disease
of immune deﬁciency, immune deprivation may be less
prominent in relatively young QFT-positive cases because
IFN-γ could be synthesized properly by stimulation with
the appropriate signals. In contrast, the response could be
altered in advance immune-deﬁciency state, as indicated
by low CD4+ T-cell counts. Therefore, it is expected that8 Clinical and Developmental Immunology
signiﬁcant numbers of false-negative reactions are present in
QFT-negativeHIVcarriers.TherelativelylowIFN-γ levelsby
mitogenstimulationinsomeoftheQFT-negativeresponders
also support this possibility. Therefore, for TB diagnosis
in advanced immunosuppression, the ratio of the IFN-γ
response/CD4+ T-cell count Elispot assay was suggested to
improve the sensitivity of the assay [33].
It is not clear why HIV infection does not diminish the
TBGLantibodytiters.ItisknownthattheCD-1presentation
pathway persists in patients with HIV, but antiglycolipid
antibodies were found to have no relationship with the
TST results [34]o rb a c i l l a r yy i e l d[ 35]. Similarly, we did
not ﬁnd any correlation between the QFT result and anti-
TBGLantibodies.Itisalsopossiblethatconcomitantnon-TB
mycobacterium infection may stimulate the TBGL antibody
synthesisinHIV-AC[7].SigniﬁcantnumbersofHIVcarriers
have antibodies to TBGL, but we could not conﬁrm if they
indicate LTBI or not.
The increases of serum IgA in advanced HIV infection
and of IgG in the early stage were already reported [36].
Although speciﬁc antibody titers in HIV infection are
decreased by some infectious agents including hepatitis B
virus but not in hepatitis A virus, probably because of
alterationsintheimmunesystemsinadvancedHIVinfection
[37], it is not known whether nonfunctional or functional
IgA was synthesized in our cases. The main limitation of the
current study is the small number of study subjects and the
lackofafollow-upstudyforestimatingtheriskofdeveloping
active tuberculosis.
Finally, to determine the correlations between biomark-
ers in infected states, we evaluated data by ROC curve
analysis (Figure 3). In this study, the plasma levels of OPN
were most speciﬁc to HIV and the levels were not elevated
in LTBI HCWs (Figure 3, Table 2). Therefore the levels can
be a good marker for active TB in non-HIV individuals,
because the OPN is known as a marker of active TB [17].
In HIV-AC, the OPN plasma levels are already elevated as
described here, and it was already reported that the levels
further increase when they developed active TB [38, 39].
It is also known that interferon-inducible protein-10 (IP-
10) and IL-18 were elevated in HIV/TB patients than in
HIV patients and suggested to be helpful in monitoring the
treatmentforpatients[38].Allthesebiomarkersweremainly
producedbymacrophages,anditwasalsoreportedthatOPN
is synthesized by macrophages as well as CD4+ T cells in
HTLV-1-induced lymphoma [40, 41].
In this study we noted elevations of anti-TBGL antibody
in LTBI in HCWs, but no link between the elevations
with LTBI in HIV-AC was conﬁrmed, probably due to the
inﬂammatory conditions in HIV.
5. Conclusion
We have found the elevation of TBGL-IgG titers in LTBI in
HCWs. In addition, the association between TBGL-IgA and
IFN-γ in HCWs was found, and it was hypothesized that the
mucosal immunity is involved in LTBI in HCWs. We could
not ﬁnd any relationships between QFT and TBGL in HIV-
AC. Low CD4+ cell count was associated with inﬂammatory
conditions as represented by high OPN in HIV-AC, which
may be the reason for ambiguous results.
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